Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
frontMIND: Tafasitamab + Lenalidomide + R-CHOP in Previously Untreated DLBCL
NCT04824092Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- May 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of tafasitamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Incyte. Primary endpoint: Progression-Free Survival by Investigator up to 43 months. Started May 2021; status: active, not recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04824092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824092.